SMARCA4 and head and neck cancer: A study in head and neck cancer found deletions of SMARCA4 as one of the most common occurrences in patients responding to ICI (61), and there have been also reports of complete remission in a patient with stage IV SMARCB1-inactivated epithelioid sarcoma (62).